Home BioVex

BioVex

acquired
-
Pharmaceutical R&D Developer

Basic Information

BioVex is a biotechnology company focused on the development and commercialization of cancer biotherapies and the prevention of infectious diseases.Their cancer program, OncoVEXGM-CSF, is an oncolytic vaccine or cancer-destroying virus technology that replicates and spreads within solid tumors, leading to cancer cell death while leaving surrounding healthy cells unharmed. The attenuated virus was also engineered to induce a strong systemic antitumor immune response.
BioVex Group Inc.
Scotland,United Kingdom
15~50 people
January 01, 1999
enquiries@biovex.com